Detection and subsequent management of fetomaternal haemorrhage (FMH) has had a significant reduction in anti-D sensitisation with improved neonatal outcomes. Detecting FMH and estimating the volume of bleed is important in determining the appropriate dose of RhD immunoglobulin (RhD Ig) for RhD negative women following a sensitising event. FMH testing may also be used when assessing fetal welfare. Dr Kidson-Gerber will discuss the current issues in FMH detection, referring to the recently updated Australian and New Zealand Society of Blood Transfusion (ANZSBT) Guidelines for laboratory estimation of FMH; and the current recommendations in management of RhD negative women, with reference to the 2021 National Blood Authority’s Prophylactic use of RhD immunoglobulin in pregnancy care.